Troriluzole

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

1 API Suppliers, 1 Listed Suppliers

DEVELOPMENTS

6 Drug(s) in Development

6 Drug(s) in Development

DIGITAL CONTENT

13 News

13 News

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: Trigriluzole, Bhv-4157a, Troriluzole [usan], 1926203-09-9, Bhv-4157, S7h48s6k7h

Molecular Formula

C₁₅H₁₆F₃N₅O₄S

Molecular Weight

419.4 g/mol

InChI Key

YBZSGIWIPOUSHY-UHFFFAOYSA-N

FDA UNII

S7H48S6K7H

Troriluzole is a formulation comprised of a prodrug form of the benzothiazole derivative riluzole, with potential anti-depressant, anxiolytic and antineoplastic activities. Following oral administration, troriluzole is converted into the active form riluzole. While the mechanism of action of riluzole is unknown, its pharmacological activities, some of which may be related to its effect, include the following: 1) an inhibitory effect on glutamate release, 2) inactivation of voltage-dependent sodium channels, and 3) interference with intracellular events that follow transmitter binding at excitatory amino acid receptors. These activities may result in myorelaxation and sedation due to the blockade of glutamatergic neurotransmission. Additionally, these activities may result in the inhibition of enzymes that are necessary for cell growth, which may decrease tumor cell growth and metastasis.

1 2D Structure

Troriluzole

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-amino-N-[2-[methyl-[2-oxo-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]ethyl]amino]-2-oxoethyl]acetamide

2.1.2 InChI

InChI=1S/C15H16F3N5O4S/c1-23(13(26)6-20-11(24)5-19)7-12(25)22-14-21-9-3-2-8(4-10(9)28-14)27-15(16,17)18/h2-4H,5-7,19H2,1H3,(H,20,24)(H,21,22,25)

2.1.3 InChI Key

YBZSGIWIPOUSHY-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CN(CC(=O)NC1=NC2=C(S1)C=C(C=C2)OC(F)(F)F)C(=O)CNC(=O)CN

2.2 Other Identifiers

2.2.1 UNII

S7H48S6K7H

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. Trigriluzole

2. Bhv-4157a

3. Troriluzole [usan]

4. 1926203-09-9

5. Bhv-4157

6. S7h48s6k7h

7. Troriluzole (usan)

8. Glycinamide, Glycylglycyl-n2-methyl-n-(6-(trifluoromethoxy)-2-benzothiazolyl)-

9. Troriluzol

10. Troriluzole [inn]

11. Unii-s7h48s6k7h

12. Bhv4157a

13. Troriluzole [who-dd]

14. Chembl4297586

15. Schembl18154275

16. Gtpl11375

17. Bhv4157

18. Db15079

19. Fc-4157

20. Sb19816

21. Hy-122487

22. Cs-0085735

23. D11414

24. Q56407722

25. Glycylglycyl-n2-methyl-n-(6-(trifluoromethoxy)-1,3-benzothiazol-2-yl)glycinamide

26. 2-(2-aminoacetamido)-n-methyl-n-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)acetamide

2.4 Create Date

2016-08-16

3 Chemical and Physical Properties

Molecular Formula	C₁₅H₁₆F₃N₅O₄S
Molecular Weight	419.4 g/mol
XLogP3	1
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	7
Exact Mass	419.08750967 g/mol
Monoisotopic Mass	419.08750967 g/mol
Topological Polar Surface Area	155 Å²
Heavy Atom Count	28
Formal Charge	0
Complexity	595
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1